Literature DB >> 15234274

Expression of human cytochrome P450 46A1 in Escherichia coli: effects of N- and C-terminal modifications.

Natalia Mast1, Ulla Andersson, Kazuo Nakayama, Ingemar Bjorkhem, Irina A Pikuleva.   

Abstract

Heterologous expression in Escherichia coli, subcellular distribution, solubility, and catalytic and substrate-binding properties of four truncated cytochromes P450 46A1 were investigated in the present study. All four lacked the N-terminal transmembrane region (residues 3-27), and, in addition, Delta 46A1H had a 4x His-tag fused to the C-terminus; H Delta 46A1 had the N-terminal 4x His-tag; H Delta 46A1 Delta had a 4x His-tag at the N-terminus and did not contain a proline-rich region at the C-terminus (residues 494-499); and Delta 46A1 Delta lacked the C-terminal proline-rich region. The truncated enzymes were expressed at 390-650 nmol/L culture levels, distributed at about a 1:1 ratio between the membrane fraction and the cytosol in low ionic strength buffer, and were predominantly monomers in detergent-free buffer. They had moderately decreased catalytic efficiencies for either cholesterol or 24S-hydroxycholesterol or both, whereas their substrate-binding constants were either unchanged or decreased 2-fold. The two forms, Delta 46A1 Delta and H Delta 46A1 Delta, both lacking the C-terminal proline-rich region seem to be good candidates for future crystallographic studies because they contain only 0.3-0.8% of high molecular weight aggregates and their catalytic efficiencies are decreased no more than 2.3-fold.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234274     DOI: 10.1016/j.abb.2004.05.012

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  17 in total

1.  The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo.

Authors:  Marjan Shafaati; Natalia Mast; Olof Beck; Rima Nayef; Gun Young Heo; Linda Björkhem-Bergman; Dieter Lütjohann; Ingemar Björkhem; Irina A Pikuleva
Journal:  J Lipid Res       Date:  2009-05-27       Impact factor: 5.922

2.  Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.

Authors:  Natalia Mast; Kyle W Anderson; Joseph B Lin; Yong Li; Illarion V Turko; Curtis Tatsuoka; Ingemar Bjorkhem; Irina A Pikuleva
Journal:  J Biol Chem       Date:  2017-02-11       Impact factor: 5.157

3.  Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity.

Authors:  Kyle W Anderson; Natalia Mast; Jeffrey W Hudgens; Joseph B Lin; Illarion V Turko; Irina A Pikuleva
Journal:  J Biol Chem       Date:  2016-04-07       Impact factor: 5.157

4.  The expression, purification and crystallization of a ubiquitin-conjugating enzyme E2 from Agrocybe aegerita underscore the impact of His-tag location on recombinant protein properties.

Authors:  De-Feng Li; Lei Feng; Yan-Jie Hou; Wei Liu
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-01-31

5.  Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice.

Authors:  Natalia Mast; Yong Li; Marlin Linger; Matthew Clark; Jeffrey Wiseman; Irina A Pikuleva
Journal:  J Biol Chem       Date:  2013-12-18       Impact factor: 5.157

6.  Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.

Authors:  Natalia Mast; Aicha Saadane; Ana Valencia-Olvera; James Constans; Erin Maxfield; Hiroyuki Arakawa; Young Li; Gary Landreth; Irina A Pikuleva
Journal:  Neuropharmacology       Date:  2017-06-24       Impact factor: 5.250

7.  Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy.

Authors:  Natalia Mast; Joseph B Lin; Irina A Pikuleva
Journal:  Mol Pharmacol       Date:  2015-06-16       Impact factor: 4.436

8.  Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.

Authors:  Natalia Mast; Mark Andrew White; Ingemar Bjorkhem; Eric F Johnson; C David Stout; Irina A Pikuleva
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-09       Impact factor: 11.205

9.  Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1.

Authors:  Natalia Mast; Wenchao Zheng; C David Stout; Irina A Pikuleva
Journal:  Mol Pharmacol       Date:  2013-04-19       Impact factor: 4.436

Review 10.  Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain.

Authors:  David W Russell; Rebekkah W Halford; Denise M O Ramirez; Rahul Shah; Tiina Kotti
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.